Invention Grant
- Patent Title: Anti-BAFFR antibody formulations
- Patent Title (中): 抗BAFFR抗体制剂
-
Application No.: US13991984Application Date: 2011-12-08
-
Publication No.: US09458240B2Publication Date: 2016-10-04
- Inventor: Marta Cosenza , Christoph Heusser , Julia Neugebauer , Eveline Schaadt , Stefanie Urlinger , Maximilian Woisetschlaeger
- Applicant: Marta Cosenza , Christoph Heusser , Julia Neugebauer , Eveline Schaadt , Stefanie Urlinger , Maximilian Woisetschlaeger
- Applicant Address: CH Basel
- Assignee: Novartis Pharma AG
- Current Assignee: Novartis Pharma AG
- Current Assignee Address: CH Basel
- Agent Grace S. Law
- International Application: PCT/EP2011/072248 WO 20111208
- International Announcement: WO2012/076670 WO 20120614
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/18 ; C07K16/28 ; A61K9/00 ; A61K9/08 ; A61K9/19 ; A61K47/18 ; A61K47/26 ; C07K14/715 ; A61K39/00

Abstract:
Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
Public/Granted literature
- US20140186373A1 ANTIBODY FORMULATION Public/Granted day:2014-07-03
Information query